Meeting
2023 ASCO Genitourinary Cancers Symposium
A phase 1/2 study of REGN4336, a PSMAxCD3 bispecific antibody, alone and in combination with cemiplimab in patients with metastatic castration-resistant prostate cancer.
Authors
William Kevin Kelly
Thomas Jefferson University, Philadelphia, PA
William Kevin Kelly , Arif Hussain , Biren Saraiya , Pradeep Thanigaimani , Furong Sun , Frank A. Seebach , Israel Lowy , Sabina Sandigursky , Elizabeth Miller
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Trials in Progress Poster Session
Session Title
Trials in Progress Poster Session A: Prostate Cancer
Track
Prostate Cancer - Advanced,Prostate Cancer - Localized
Sub Track
Therapeutics
Clinical Trial Registration Number
NCT03088540
Citation
J Clin Oncol 41, 2023 (suppl 6; abstr TPS284)
DOI
10.1200/JCO.2023.41.6_suppl.TPS284
Abstract #
TPS284
Poster Bd #
Q6
Abstract Disclosures
Similar Posters
Poster
2021 Genitourinary Cancers Symposium
A phase I/II study of REGN5678 (Anti-PSMAxCD28, a costimulatory bispecific antibody) with cemiplimab (anti–PD-1) in patients with metastatic castration-resistant prostate cancer.
First Author: Jingsong Zhang
Poster
2022 ASCO Genitourinary Cancers Symposium
Phase I/II trial of pembrolizumab and AR signaling inhibitor +/- 225Ac-J591 for chemo-naive metastatic castration-resistant prostate cancer (mCRPC).
First Author: Scott T. Tagawa
Poster
2019 Genitourinary Cancers Symposium
Phase I/II dose-escalation trial of fractionated dose 177Lu-J591 plus 177Lu-PSMA-617 for metastatic castration-resistant prostate cancer (mCRPC).
First Author: Scott T. Tagawa
Poster
2024 ASCO Genitourinary Cancers Symposium
Safety, tolerability, and dosimetry of 177Lu-TLX591 with best standard of care in patients with PSMA-expressing metastatic castration-resistant prostate cancer (ProstAct-SELECT).
First Author: Nat Lenzo